NCT01081262 · OUTCOME

Participants With Grade 1 or Higher Non-serious Adverse Effects Assessed by CTCAE Version 4.0

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer · Source last updated 2026-08-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: Every cycle while on treatment, up to 5 years

What was measured

Grade 1 or higher non-serious adverse events were graded by CTC AE v 4.

Analysis population: Eligible and treated patients

Groups in this outcome

Arm I (Carboplatin and Paclitaxel)

Patients receive carboplatin IV over 30-60 minutes on day 1 and paclitaxel IV over 3 hours on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Carboplatin: Given IV Laboratory Biomarker Analysis: Correlative studies Paclitaxel: Given IV Quality-of-Life Assessment: Ancillary studies

Arm II (Oxaliplatin and Capecitabine)

Patients receive oxaliplatin IV over 2-6 hours on day 1 and capecitabine PO BID on days 1-14. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Capecitabine: Given PO Laboratory Biomarker Analysis: Correlative studies Oxaliplatin: Given IV Quality-of-Life Assessment: Ancillary studies

Arm III (Carboplatin, Paclitaxel, Bevacizumab)

Patients receive carboplatin and paclitaxel IV as in arm I and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-90 minutes alone on day 1. Treatment repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity. Bevacizumab: Given IV Carboplatin: Given IV Laboratory Biomarker Analysis: Correlative studies Paclitaxel: Given IV Quality-of-Life Assessment: Ancillary studies

Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)

Patients receive oxaliplatin and capecitabine as in arm II, and bevacizumab as in arm III. Bevacizumab: Given IV Capecitabine: Given PO Laboratory Biomarker Analysis: Correlative studies Oxaliplatin: Given IV Quality-of-Life Assessment: Ancillary studies

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Arm I (Carboplatin and Paclitaxel)	13
Arm II (Oxaliplatin and Capecitabine)	13
Arm III (Carboplatin, Paclitaxel, Bevacizumab)	13
Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)	11

Reported measurements

Abnormal lab values

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I (Carboplatin and Paclitaxel)	8	Not reported	Not reported	Not reported	Not reported
Arm II (Oxaliplatin and Capecitabine)	10	Not reported	Not reported	Not reported	Not reported
Arm III (Carboplatin, Paclitaxel, Bevacizumab)	10	Not reported	Not reported	Not reported	Not reported
Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)	10	Not reported	Not reported	Not reported	Not reported

Allergic reaction

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I (Carboplatin and Paclitaxel)	3	Not reported	Not reported	Not reported	Not reported
Arm II (Oxaliplatin and Capecitabine)	1	Not reported	Not reported	Not reported	Not reported
Arm III (Carboplatin, Paclitaxel, Bevacizumab)	0	Not reported	Not reported	Not reported	Not reported
Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)	4	Not reported	Not reported	Not reported	Not reported

Allergic rhinitis

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I (Carboplatin and Paclitaxel)	0	Not reported	Not reported	Not reported	Not reported
Arm II (Oxaliplatin and Capecitabine)	1	Not reported	Not reported	Not reported	Not reported
Arm III (Carboplatin, Paclitaxel, Bevacizumab)	1	Not reported	Not reported	Not reported	Not reported
Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)	1	Not reported	Not reported	Not reported	Not reported

Alopecia

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I (Carboplatin and Paclitaxel)	11	Not reported	Not reported	Not reported	Not reported
Arm II (Oxaliplatin and Capecitabine)	1	Not reported	Not reported	Not reported	Not reported
Arm III (Carboplatin, Paclitaxel, Bevacizumab)	9	Not reported	Not reported	Not reported	Not reported
Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)	5	Not reported	Not reported	Not reported	Not reported

Anemia

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I (Carboplatin and Paclitaxel)	12	Not reported	Not reported	Not reported	Not reported
Arm II (Oxaliplatin and Capecitabine)	7	Not reported	Not reported	Not reported	Not reported
Arm III (Carboplatin, Paclitaxel, Bevacizumab)	4	Not reported	Not reported	Not reported	Not reported
Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)	6	Not reported	Not reported	Not reported	Not reported

Bleeding

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I (Carboplatin and Paclitaxel)	1	Not reported	Not reported	Not reported	Not reported
Arm II (Oxaliplatin and Capecitabine)	1	Not reported	Not reported	Not reported	Not reported
Arm III (Carboplatin, Paclitaxel, Bevacizumab)	3	Not reported	Not reported	Not reported	Not reported
Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)	5	Not reported	Not reported	Not reported	Not reported

Cold-like symptoms

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I (Carboplatin and Paclitaxel)	2	Not reported	Not reported	Not reported	Not reported
Arm II (Oxaliplatin and Capecitabine)	3	Not reported	Not reported	Not reported	Not reported
Arm III (Carboplatin, Paclitaxel, Bevacizumab)	7	Not reported	Not reported	Not reported	Not reported
Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)	6	Not reported	Not reported	Not reported	Not reported

Constipation

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I (Carboplatin and Paclitaxel)	3	Not reported	Not reported	Not reported	Not reported
Arm II (Oxaliplatin and Capecitabine)	4	Not reported	Not reported	Not reported	Not reported
Arm III (Carboplatin, Paclitaxel, Bevacizumab)	7	Not reported	Not reported	Not reported	Not reported
Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)	9	Not reported	Not reported	Not reported	Not reported

Diarrhea

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I (Carboplatin and Paclitaxel)	5	Not reported	Not reported	Not reported	Not reported
Arm II (Oxaliplatin and Capecitabine)	6	Not reported	Not reported	Not reported	Not reported
Arm III (Carboplatin, Paclitaxel, Bevacizumab)	5	Not reported	Not reported	Not reported	Not reported
Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)	8	Not reported	Not reported	Not reported	Not reported

dyspnea

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I (Carboplatin and Paclitaxel)	2	Not reported	Not reported	Not reported	Not reported
Arm II (Oxaliplatin and Capecitabine)	1	Not reported	Not reported	Not reported	Not reported
Arm III (Carboplatin, Paclitaxel, Bevacizumab)	3	Not reported	Not reported	Not reported	Not reported
Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)	0	Not reported	Not reported	Not reported	Not reported

Edema Limbs

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I (Carboplatin and Paclitaxel)	0	Not reported	Not reported	Not reported	Not reported
Arm II (Oxaliplatin and Capecitabine)	1	Not reported	Not reported	Not reported	Not reported
Arm III (Carboplatin, Paclitaxel, Bevacizumab)	0	Not reported	Not reported	Not reported	Not reported
Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)	0	Not reported	Not reported	Not reported	Not reported

Fatigue

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I (Carboplatin and Paclitaxel)	10	Not reported	Not reported	Not reported	Not reported
Arm II (Oxaliplatin and Capecitabine)	10	Not reported	Not reported	Not reported	Not reported
Arm III (Carboplatin, Paclitaxel, Bevacizumab)	8	Not reported	Not reported	Not reported	Not reported
Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)	11	Not reported	Not reported	Not reported	Not reported

Fever

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I (Carboplatin and Paclitaxel)	3	Not reported	Not reported	Not reported	Not reported
Arm II (Oxaliplatin and Capecitabine)	0	Not reported	Not reported	Not reported	Not reported
Arm III (Carboplatin, Paclitaxel, Bevacizumab)	2	Not reported	Not reported	Not reported	Not reported
Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)	1	Not reported	Not reported	Not reported	Not reported

Hand/Foot Syndrome

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I (Carboplatin and Paclitaxel)	1	Not reported	Not reported	Not reported	Not reported
Arm II (Oxaliplatin and Capecitabine)	0	Not reported	Not reported	Not reported	Not reported
Arm III (Carboplatin, Paclitaxel, Bevacizumab)	0	Not reported	Not reported	Not reported	Not reported
Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)	7	Not reported	Not reported	Not reported	Not reported

Headache

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I (Carboplatin and Paclitaxel)	3	Not reported	Not reported	Not reported	Not reported
Arm II (Oxaliplatin and Capecitabine)	4	Not reported	Not reported	Not reported	Not reported
Arm III (Carboplatin, Paclitaxel, Bevacizumab)	5	Not reported	Not reported	Not reported	Not reported
Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)	4	Not reported	Not reported	Not reported	Not reported

Hypertension

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I (Carboplatin and Paclitaxel)	3	Not reported	Not reported	Not reported	Not reported
Arm II (Oxaliplatin and Capecitabine)	8	Not reported	Not reported	Not reported	Not reported
Arm III (Carboplatin, Paclitaxel, Bevacizumab)	9	Not reported	Not reported	Not reported	Not reported
Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)	10	Not reported	Not reported	Not reported	Not reported

Hypomagnesemia

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I (Carboplatin and Paclitaxel)	1	Not reported	Not reported	Not reported	Not reported
Arm II (Oxaliplatin and Capecitabine)	0	Not reported	Not reported	Not reported	Not reported
Arm III (Carboplatin, Paclitaxel, Bevacizumab)	2	Not reported	Not reported	Not reported	Not reported
Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)	0	Not reported	Not reported	Not reported	Not reported

Infection

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I (Carboplatin and Paclitaxel)	4	Not reported	Not reported	Not reported	Not reported
Arm II (Oxaliplatin and Capecitabine)	0	Not reported	Not reported	Not reported	Not reported
Arm III (Carboplatin, Paclitaxel, Bevacizumab)	3	Not reported	Not reported	Not reported	Not reported
Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)	3	Not reported	Not reported	Not reported	Not reported

Laryngeal Spasm

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I (Carboplatin and Paclitaxel)	0	Not reported	Not reported	Not reported	Not reported
Arm II (Oxaliplatin and Capecitabine)	4	Not reported	Not reported	Not reported	Not reported
Arm III (Carboplatin, Paclitaxel, Bevacizumab)	0	Not reported	Not reported	Not reported	Not reported
Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)	0	Not reported	Not reported	Not reported	Not reported

Low Lymphocytes

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I (Carboplatin and Paclitaxel)	1	Not reported	Not reported	Not reported	Not reported
Arm II (Oxaliplatin and Capecitabine)	1	Not reported	Not reported	Not reported	Not reported
Arm III (Carboplatin, Paclitaxel, Bevacizumab)	2	Not reported	Not reported	Not reported	Not reported
Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)	0	Not reported	Not reported	Not reported	Not reported

Low Mood

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I (Carboplatin and Paclitaxel)	1	Not reported	Not reported	Not reported	Not reported
Arm II (Oxaliplatin and Capecitabine)	2	Not reported	Not reported	Not reported	Not reported
Arm III (Carboplatin, Paclitaxel, Bevacizumab)	1	Not reported	Not reported	Not reported	Not reported
Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)	1	Not reported	Not reported	Not reported	Not reported

Low Neutrophils

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I (Carboplatin and Paclitaxel)	7	Not reported	Not reported	Not reported	Not reported
Arm II (Oxaliplatin and Capecitabine)	5	Not reported	Not reported	Not reported	Not reported
Arm III (Carboplatin, Paclitaxel, Bevacizumab)	4	Not reported	Not reported	Not reported	Not reported
Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)	7	Not reported	Not reported	Not reported	Not reported

Low platelets

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I (Carboplatin and Paclitaxel)	8	Not reported	Not reported	Not reported	Not reported
Arm II (Oxaliplatin and Capecitabine)	3	Not reported	Not reported	Not reported	Not reported
Arm III (Carboplatin, Paclitaxel, Bevacizumab)	5	Not reported	Not reported	Not reported	Not reported
Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)	7	Not reported	Not reported	Not reported	Not reported

Low white Blood Cells

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I (Carboplatin and Paclitaxel)	5	Not reported	Not reported	Not reported	Not reported
Arm II (Oxaliplatin and Capecitabine)	5	Not reported	Not reported	Not reported	Not reported
Arm III (Carboplatin, Paclitaxel, Bevacizumab)	4	Not reported	Not reported	Not reported	Not reported
Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)	6	Not reported	Not reported	Not reported	Not reported

Mucositis

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I (Carboplatin and Paclitaxel)	1	Not reported	Not reported	Not reported	Not reported
Arm II (Oxaliplatin and Capecitabine)	1	Not reported	Not reported	Not reported	Not reported
Arm III (Carboplatin, Paclitaxel, Bevacizumab)	1	Not reported	Not reported	Not reported	Not reported
Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)	3	Not reported	Not reported	Not reported	Not reported

Nausea/Vomiting

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I (Carboplatin and Paclitaxel)	8	Not reported	Not reported	Not reported	Not reported
Arm II (Oxaliplatin and Capecitabine)	8	Not reported	Not reported	Not reported	Not reported
Arm III (Carboplatin, Paclitaxel, Bevacizumab)	9	Not reported	Not reported	Not reported	Not reported
Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)	9	Not reported	Not reported	Not reported	Not reported

Oral Problems

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I (Carboplatin and Paclitaxel)	3	Not reported	Not reported	Not reported	Not reported
Arm II (Oxaliplatin and Capecitabine)	2	Not reported	Not reported	Not reported	Not reported
Arm III (Carboplatin, Paclitaxel, Bevacizumab)	4	Not reported	Not reported	Not reported	Not reported
Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)	9	Not reported	Not reported	Not reported	Not reported

Other

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I (Carboplatin and Paclitaxel)	4	Not reported	Not reported	Not reported	Not reported
Arm II (Oxaliplatin and Capecitabine)	4	Not reported	Not reported	Not reported	Not reported
Arm III (Carboplatin, Paclitaxel, Bevacizumab)	7	Not reported	Not reported	Not reported	Not reported
Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)	7	Not reported	Not reported	Not reported	Not reported

Other GI Problems

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I (Carboplatin and Paclitaxel)	8	Not reported	Not reported	Not reported	Not reported
Arm II (Oxaliplatin and Capecitabine)	6	Not reported	Not reported	Not reported	Not reported
Arm III (Carboplatin, Paclitaxel, Bevacizumab)	7	Not reported	Not reported	Not reported	Not reported
Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)	6	Not reported	Not reported	Not reported	Not reported

Pain

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I (Carboplatin and Paclitaxel)	9	Not reported	Not reported	Not reported	Not reported
Arm II (Oxaliplatin and Capecitabine)	6	Not reported	Not reported	Not reported	Not reported
Arm III (Carboplatin, Paclitaxel, Bevacizumab)	7	Not reported	Not reported	Not reported	Not reported
Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)	7	Not reported	Not reported	Not reported	Not reported

Peripheral/Sensory Neuropathy

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I (Carboplatin and Paclitaxel)	11	Not reported	Not reported	Not reported	Not reported
Arm II (Oxaliplatin and Capecitabine)	11	Not reported	Not reported	Not reported	Not reported
Arm III (Carboplatin, Paclitaxel, Bevacizumab)	8	Not reported	Not reported	Not reported	Not reported
Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)	10	Not reported	Not reported	Not reported	Not reported

Pneumothorax

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I (Carboplatin and Paclitaxel)	0	Not reported	Not reported	Not reported	Not reported
Arm II (Oxaliplatin and Capecitabine)	1	Not reported	Not reported	Not reported	Not reported
Arm III (Carboplatin, Paclitaxel, Bevacizumab)	0	Not reported	Not reported	Not reported	Not reported
Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)	0	Not reported	Not reported	Not reported	Not reported

Raised CA19-9

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I (Carboplatin and Paclitaxel)	0	Not reported	Not reported	Not reported	Not reported
Arm II (Oxaliplatin and Capecitabine)	0	Not reported	Not reported	Not reported	Not reported
Arm III (Carboplatin, Paclitaxel, Bevacizumab)	2	Not reported	Not reported	Not reported	Not reported
Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)	0	Not reported	Not reported	Not reported	Not reported

Raised Blood Counts

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I (Carboplatin and Paclitaxel)	1	Not reported	Not reported	Not reported	Not reported
Arm II (Oxaliplatin and Capecitabine)	1	Not reported	Not reported	Not reported	Not reported
Arm III (Carboplatin, Paclitaxel, Bevacizumab)	0	Not reported	Not reported	Not reported	Not reported
Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)	1	Not reported	Not reported	Not reported	Not reported

Rash

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I (Carboplatin and Paclitaxel)	4	Not reported	Not reported	Not reported	Not reported
Arm II (Oxaliplatin and Capecitabine)	2	Not reported	Not reported	Not reported	Not reported
Arm III (Carboplatin, Paclitaxel, Bevacizumab)	3	Not reported	Not reported	Not reported	Not reported
Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)	4	Not reported	Not reported	Not reported	Not reported

Stomatitis

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I (Carboplatin and Paclitaxel)	0	Not reported	Not reported	Not reported	Not reported
Arm II (Oxaliplatin and Capecitabine)	2	Not reported	Not reported	Not reported	Not reported
Arm III (Carboplatin, Paclitaxel, Bevacizumab)	1	Not reported	Not reported	Not reported	Not reported
Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)	0	Not reported	Not reported	Not reported	Not reported

Taste Alteration

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I (Carboplatin and Paclitaxel)	3	Not reported	Not reported	Not reported	Not reported
Arm II (Oxaliplatin and Capecitabine)	2	Not reported	Not reported	Not reported	Not reported
Arm III (Carboplatin, Paclitaxel, Bevacizumab)	1	Not reported	Not reported	Not reported	Not reported
Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)	2	Not reported	Not reported	Not reported	Not reported

Urinary Problems

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I (Carboplatin and Paclitaxel)	1	Not reported	Not reported	Not reported	Not reported
Arm II (Oxaliplatin and Capecitabine)	0	Not reported	Not reported	Not reported	Not reported
Arm III (Carboplatin, Paclitaxel, Bevacizumab)	1	Not reported	Not reported	Not reported	Not reported
Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)	2	Not reported	Not reported	Not reported	Not reported

Vaginal Bleeding

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I (Carboplatin and Paclitaxel)	0	Not reported	Not reported	Not reported	Not reported
Arm II (Oxaliplatin and Capecitabine)	1	Not reported	Not reported	Not reported	Not reported
Arm III (Carboplatin, Paclitaxel, Bevacizumab)	1	Not reported	Not reported	Not reported	Not reported
Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)	2	Not reported	Not reported	Not reported	Not reported

Weight Gain

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I (Carboplatin and Paclitaxel)	0	Not reported	Not reported	Not reported	Not reported
Arm II (Oxaliplatin and Capecitabine)	1	Not reported	Not reported	Not reported	Not reported
Arm III (Carboplatin, Paclitaxel, Bevacizumab)	1	Not reported	Not reported	Not reported	Not reported
Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)	2	Not reported	Not reported	Not reported	Not reported

Weight Loss

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I (Carboplatin and Paclitaxel)	2	Not reported	Not reported	Not reported	Not reported
Arm II (Oxaliplatin and Capecitabine)	3	Not reported	Not reported	Not reported	Not reported
Arm III (Carboplatin, Paclitaxel, Bevacizumab)	4	Not reported	Not reported	Not reported	Not reported
Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)	5	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
8
group Id
OG001
value
10
group Id
OG002
value
10
group Id
OG003
value
10
title
Abnormal lab values
categories
measurements
group Id
OG000
value
3
group Id
OG001
value
1
group Id
OG002
value
0
group Id
OG003
value
4
title
Allergic reaction
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
1
group Id
OG002
value
1
group Id
OG003
value
1
title
Allergic rhinitis
categories
measurements
group Id
OG000
value
11
group Id
OG001
value
1
group Id
OG002
value
9
group Id
OG003
value
5
title
Alopecia
categories
measurements
group Id
OG000
value
12
group Id
OG001
value
7
group Id
OG002
value
4
group Id
OG003
value
6
title
Anemia
categories
measurements
group Id
OG000
value
1
group Id
OG001
value
1
group Id
OG002
value
3
group Id
OG003
value
5
title
Bleeding
categories
measurements
group Id
OG000
value
2
group Id
OG001
value
3
group Id
OG002
value
7
group Id
OG003
value
6
title
Cold-like symptoms
categories
measurements
group Id
OG000
value
3
group Id
OG001
value
4
group Id
OG002
value
7
group Id
OG003
value
9
title
Constipation
categories
measurements
group Id
OG000
value
5
group Id
OG001
value
6
group Id
OG002
value
5
group Id
OG003
value
8
title
Diarrhea
categories
measurements
group Id
OG000
value
2
group Id
OG001
value
1
group Id
OG002
value
3
group Id
OG003
value
0
title
dyspnea
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
1
group Id
OG002
value
0
group Id
OG003
value
0
title
Edema Limbs
categories
measurements
group Id
OG000
value
10
group Id
OG001
value
10
group Id
OG002
value
8
group Id
OG003
value
11
title
Fatigue

denoms

counts
group Id
OG000
value
13
group Id
OG001
value
13
group Id
OG002
value
13
group Id
OG003
value
11
units
Participants

description

Grade 1 or higher non-serious adverse events were graded by CTC AE v 4.

groups

description
Patients receive carboplatin IV over 30-60 minutes on day 1 and paclitaxel IV over 3 hours on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Carboplatin: Given IV Laboratory Biomarker Analysis: Correlative studies Paclitaxel: Given IV Quality-of-Life Assessment: Ancillary studies
id
OG000
title
Arm I (Carboplatin and Paclitaxel)
description
Patients receive oxaliplatin IV over 2-6 hours on day 1 and capecitabine PO BID on days 1-14. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Capecitabine: Given PO Laboratory Biomarker Analysis: Correlative studies Oxaliplatin: Given IV Quality-of-Life Assessment: Ancillary studies
id
OG001
title
Arm II (Oxaliplatin and Capecitabine)
description
Patients receive carboplatin and paclitaxel IV as in arm I and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-90 minutes alone on day 1. Treatment repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity. Bevacizumab: Given IV Carboplatin: Given IV Laboratory Biomarker Analysis: Correlative studies Paclitaxel: Given IV Quality-of-Life Assessment: Ancillary studies
id
OG002
title
Arm III (Carboplatin, Paclitaxel, Bevacizumab)
description
Patients receive oxaliplatin and capecitabine as in arm II, and bevacizumab as in arm III. Bevacizumab: Given IV Capecitabine: Given PO Laboratory Biomarker Analysis: Correlative studies Oxaliplatin: Given IV Quality-of-Life Assessment: Ancillary studies
id
OG003
title
Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)

param Type

COUNT_OF_PARTICIPANTS

population Description

Eligible and treated patients

reporting Status

POSTED

time Frame

Every cycle while on treatment, up to 5 years

title

Participants With Grade 1 or Higher Non-serious Adverse Effects Assessed by CTCAE Version 4.0

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice